A Phase 1 interventional study of CD388 Injection and Saline placebo in Healthy, sponsored by Cidara Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Cidara Therapeutics Inc. (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when dosed by subcutaneous (SQ) administration as a single dose to healthy Japanese adult subjects.
This is a Phase 1, single-center, prospective, randomized, double-blind study of ascending single doses of CD388 Injection administered SQ to healthy Japanese adult subjects. The goals are to assess safety, tolerability, and pharmacokinetics (PK) of CD388.
Cidara Therapeutics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject must meet one of the following criteria:
Normal clinical examination, including:
Exclusion Criteria:
History of any of the following:
Subjects with one or more of the following laboratory abnormalities at screening as defined by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1 (DAIDS 2017):
Any other laboratory abnormality considered to be clinically significant by the Investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9 subjects randomized in a 7:2 ratio to receive either 50 mg CD388 SQ injection or matching placebo injection
Combination Product: CD388 Injection · Drug: Saline placebo
9 subjects randomized in a 7:2 ratio to receive either 150 mg CD388 SQ injection or matching placebo injection
Combination Product: CD388 Injection · Drug: Saline placebo
9 subjects randomized in a 7:2 ratio to receive either 450 mg CD388 SQ injection or matching placebo injection
Combination Product: CD388 Injection · Drug: Saline placebo
CD388 liquid for injection
Sterile normal saline for injection
Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388
Number of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
Time frame: From Day 1 through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others)
Severity of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388
Severity of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
Time frame: From Day 1 through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others)
Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration
Evaluation of the maximum plasma concentration (Cmax) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration
Evaluation of the time to maximum plasma concentration (Tmax) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Terminal Elimination Half-life (t½) Following CD388 Injection Administration
Evaluation of the terminal elimination half-life (t½) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Apparent Clearance (CL/F) Following CD388 Injection Administration
Evaluation of the apparent clearance (CL/F) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration
Evaluation of the apparent volume of distribution (VZ/F) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-last]) Following CD388 Injection Administration
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-last\]) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following subcutaneous administration of a single dose of CD388.
Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
The planned total enrollment was 27 participants. One participant in the 150 milligram (mg) CD388 arm withdrew consent shortly after dosing and was replaced, resulting in an overall enrollment of 28 participants.
| Milestone | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo |
|---|---|---|---|---|
| Started | 7 | 8 | 7 | 6 |
| Completed | 7 | 6 | 6 | 5 |
| Not completed | 0 | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
Number of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
| events | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo |
|---|---|---|---|---|
| Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 | 7 | 3 | 6 | 2 |
Severity of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
| events | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo |
|---|---|---|---|---|
| Grade 1 (Mild) | 7 | 3 | 6 | 2 |
| Grade 2 (Moderate) | 0 | 0 | 0 | 0 |
| Grade 3 (Severe) | 0 | 0 | 0 | 0 |
Evaluation of the maximum plasma concentration (Cmax) following subcutaneous administration of a single dose of CD388.
| micrograms/milliliter (ug/mL) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration | 3.87 ± 0.776 | 13.5 ± 4.10 | 41.7 ± 9.27 |
Evaluation of the time to maximum plasma concentration (Tmax) following subcutaneous administration of a single dose of CD388.
| hours (h) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration | 312.00 (192.00 to 313.03) | 97.00 (48.00 to 313.00) | 144.00 (72.00 to 312.02) |
Evaluation of the terminal elimination half-life (t½) following subcutaneous administration of a single dose of CD388.
| hours (h) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Terminal Elimination Half-life (t½) Following CD388 Injection Administration | 1325.86 ± 289.24 | 1284.26 ± 389.61 | 1210.10 ± 193.31 |
Evaluation of the apparent clearance (CL/F) following subcutaneous administration of a single dose of CD388.
| liters/hour (L/h) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Apparent Clearance (CL/F) Following CD388 Injection Administration | 0.00653 ± 0.000529 | 0.00723 ± 0.00200 | 0.00764 ± 0.00144 |
Evaluation of the apparent volume of distribution (VZ/F) following subcutaneous administration of a single dose of CD388.
| liters (L) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration | 12.5 ± 2.87 | 12.6 ± 3.42 | 13.3 ± 3.10 |
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-last\]) following subcutaneous administration of a single dose of CD388.
| ug*h/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-last]) Following CD388 Injection Administration | 5880 ± 615 | 18900 ± 5730 | 53300 ± 8320 |
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following subcutaneous administration of a single dose of CD388.
| ug*h/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration | 7700 ± 657 | 22200 ± 6390 | 60600 ± 10700 |
Collected over Adverse events were collected for all participants from the time of signing the informed consent form through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50 mg CD388 | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| 150 mg CD388 | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| 450 mg CD388 | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Pooled Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo |
|---|---|---|---|---|
| FatigueGeneral disorders | 2/7 | 0/8 | 0/7 | 1/6 |
| Injection site hemorrhageGeneral disorders | 0/7 | 0/8 | 2/7 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/7 | 0/8 | 2/7 | 0/6 |
| ConstipationGastrointestinal disorders | 1/7 | 1/8 | 0/7 | 1/6 |
| Influenza like illnessGeneral disorders | 1/7 | 0/8 | 0/7 | 0/6 |
| Asymptomatic COVID-19Infections and infestations | 1/7 | 0/8 | 1/7 | 0/6 |
| COVID-19Infections and infestations | 1/7 | 1/8 | 0/7 | 0/6 |
| HeadacheNervous system disorders | 1/7 | 0/8 | 1/7 | 0/6 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 0/7 | 0/8 | 1/7 | 0/6 |
| Injection site erythemaGeneral disorders | 0/7 | 1/8 | 0/7 | 0/6 |
The Safety Population analyzed consisted of all participants who received any amount of study drug.
| Age, Continuous(years) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Mean | 51.4 ± 13.60 | 50.4 ± 11.90 | 46.0 ± 15.35 | 49.8 ± 15.99 | 49.4 ± 13.49 |
| Age, Continuous(years) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Median | 54.0 (22 to 62) | 55.0 (26 to 64) | 47.0 (21 to 65) | 54.5 (20 to 63) | 54.0 (20 to 65) |
| Sex: Female, Male(Participants) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 3 | 2 | 2 | 12 |
| Male | 2 | 5 | 5 | 4 | 16 |
| Ethnicity (NIH/OMB)(Participants) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 8 | 7 | 6 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 7 | 8 | 7 | 6 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| United States | 7 | 8 | 7 | 6 | 28 |
| Weight(kilograms (kg)) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Mean | 62.84 ± 7.917 | 69.71 ± 11.421 | 73.27 ± 14.517 | 68.55 ± 7.073 | 68.64 ± 10.884 |
| Weight(kg) | 50 mg CD388 | 150 mg CD388 | 450 mg CD388 | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Median | 61.50 (52.5 to 74.9) | 74.10 (51.8 to 84.9) | 77.10 (51.7 to 90.9) | 66.10 (61.1 to 77.6) | 67.15 (51.7 to 90.9) |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Jul 2023, 8 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.